The association of neuropathy with monoclonal gammopathy has been known for several years, even if the nosological position of these neuropathies is still debated. Similarly unsettled is the pathogenetic role and diagnostic relevance in clinical practice of the antineural antibodies frequently associated with monoclonal gammopathies of undetermined significance of IgM isotype, as well as the most effective therapy (if any) to be used in these patients. Over the past 12 months these issues have been addressed in several papers whose results will be critically reviewed here.